India · Delayed Price · Currency is INR Indoco Remedies Statistics
Total Valuation
Indoco Remedies has a market cap or net worth of INR 24.02 billion. The enterprise value is 34.52 billion.
| Market Cap | 24.02B |
| Enterprise Value | 34.52B |
Important Dates
The next estimated earnings date is Tuesday, July 21, 2026.
| Earnings Date | Jul 21, 2026 |
| Ex-Dividend Date | Sep 4, 2025 |
Share Statistics
Indoco Remedies has 92.30 million shares outstanding. The number of shares has decreased by -3.55% in one year.
| Current Share Class | 92.30M |
| Shares Outstanding | 92.30M |
| Shares Change (YoY) | -3.55% |
| Shares Change (QoQ) | -9.55% |
| Owned by Insiders (%) | 22.34% |
| Owned by Institutions (%) | 21.16% |
| Float | 36.08M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 33.15 |
| PS Ratio | 1.30 |
| PB Ratio | 2.58 |
| P/TBV Ratio | 3.25 |
| P/FCF Ratio | 53.74 |
| P/OCF Ratio | 12.50 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 24.34, with an EV/FCF ratio of 77.22.
| EV / Earnings | n/a |
| EV / Sales | 1.87 |
| EV / EBITDA | 24.34 |
| EV / EBIT | 224.86 |
| EV / FCF | 77.22 |
Financial Position
The company has a current ratio of 1.13, with a Debt / Equity ratio of 1.17.
| Current Ratio | 1.13 |
| Quick Ratio | 0.52 |
| Debt / Equity | 1.17 |
| Debt / EBITDA | 7.69 |
| Debt / FCF | 24.38 |
| Interest Coverage | 0.13 |
Financial Efficiency
Return on equity (ROE) is -10.12% and return on invested capital (ROIC) is 0.78%.
| Return on Equity (ROE) | -10.12% |
| Return on Assets (ROA) | 0.38% |
| Return on Invested Capital (ROIC) | 0.78% |
| Return on Capital Employed (ROCE) | 1.00% |
| Weighted Average Cost of Capital (WACC) | 7.78% |
| Revenue Per Employee | 3.08M |
| Profits Per Employee | -158,583 |
| Employee Count | 6,000 |
| Asset Turnover | 0.73 |
| Inventory Turnover | 1.31 |
Taxes
| Income Tax | -78.10M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -22.18% in the last 52 weeks. The beta is 0.55, so Indoco Remedies's price volatility has been lower than the market average.
| Beta (5Y) | 0.55 |
| 52-Week Price Change | -22.18% |
| 50-Day Moving Average | 224.21 |
| 200-Day Moving Average | 232.81 |
| Relative Strength Index (RSI) | 68.61 |
| Average Volume (20 Days) | 405,417 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Indoco Remedies had revenue of INR 18.45 billion and -951.50 million in losses. Loss per share was -10.70.
| Revenue | 18.45B |
| Gross Profit | 13.04B |
| Operating Income | 153.50M |
| Pretax Income | -1.07B |
| Net Income | -951.50M |
| EBITDA | 1.42B |
| EBIT | 153.50M |
| Loss Per Share | -10.70 |
Balance Sheet
The company has 329.90 million in cash and 10.90 billion in debt, with a net cash position of -10.57 billion or -114.49 per share.
| Cash & Cash Equivalents | 329.90M |
| Total Debt | 10.90B |
| Net Cash | -10.57B |
| Net Cash Per Share | -114.49 |
| Equity (Book Value) | 9.32B |
| Book Value Per Share | 111.55 |
| Working Capital | 1.41B |
Cash Flow
In the last 12 months, operating cash flow was 1.92 billion and capital expenditures -1.48 billion, giving a free cash flow of 447.00 million.
| Operating Cash Flow | 1.92B |
| Capital Expenditures | -1.48B |
| Depreciation & Amortization | 1.26B |
| Net Borrowing | 468.60M |
| Free Cash Flow | 447.00M |
| FCF Per Share | 4.84 |
Margins
Gross margin is 70.64%, with operating and profit margins of 0.83% and -5.16%.
| Gross Margin | 70.64% |
| Operating Margin | 0.83% |
| Pretax Margin | -5.77% |
| Profit Margin | -5.16% |
| EBITDA Margin | 7.68% |
| EBIT Margin | 0.83% |
| FCF Margin | 2.42% |
Dividends & Yields
This stock pays an annual dividend of 0.20, which amounts to a dividend yield of 0.08%.
| Dividend Per Share | 0.20 |
| Dividend Yield | 0.08% |
| Dividend Growth (YoY) | -86.67% |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 3.55% |
| Shareholder Yield | 3.62% |
| Earnings Yield | -3.96% |
| FCF Yield | 1.86% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for Indoco Remedies is 276.25, which is 6.66% higher than the current price. The consensus rating is "Hold".
| Price Target | 276.25 |
| Price Target Difference | 6.66% |
| Analyst Consensus | Hold |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
The last stock split was on May 17, 2012. It was a forward split with a ratio of 7.5.
| Last Split Date | May 17, 2012 |
| Split Type | Forward |
| Split Ratio | 7.5 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 6 |